The immune system has several signaling pathways that detect invading pathogens. When activated in certain conditions, these pathways can also serve to exacerbate or even cause autoimmune disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kim Caesar
References
Tian, J. et al. Nat. Immunol. 8, 487–496 (2007).
Creagh, E.M. & O'Neill, L.A. Trends Immunol. 27, 352–357 (2006).
Akira, S., Uematsu, S. & Takeuchi, O. Cell 124, 783–801 (2006).
Leadbetter, E.A. et al. Nature 416, 603–607 (2002).
Vollmer, J. et al. J. Exp. Med. 202, 1575–1585 (2005).
Lovgren, T. et al. Arthritis Rheum. 54, 1917–1927 (2006).
Barrat, F.J. et al. J. Exp. Med. 202, 1131–1139 (2005).
Lotze, M.T. & Tracey, K.J. Nat. Rev. Immunol. 5, 331–342 (2005).
Scaffidi, P., Misteli, T. & Bianchi, M.E. Nature 418, 191–195 (2002).
Palumbo, R. et al. J. Cell. Biol. 164, 441–449 (2004).
Bonaldi, T. et al. EMBO J. 22, 5551–5560 (2003).
Dumitriu, I.E., Baruah, P., Bianchi, M.E., Manfredi, A.A. & Rovere-Querini, P. Eur. J. Immunol. 35, 2184–2190 (2005).
Popovic, P.J. et al. J. Immunol. 177, 8701–8707 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A.M.K. is an employee and shareholder of Coley Pharmaceutical Group, which is developing drugs targeting TLR9.
Rights and permissions
About this article
Cite this article
Krieg, A. TLR9 and DNA 'feel' RAGE. Nat Immunol 8, 475–477 (2007). https://doi.org/10.1038/ni0507-475
Issue Date:
DOI: https://doi.org/10.1038/ni0507-475
This article is cited by
-
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib
Leukemia (2014)
-
TLR7 and TLR9 in SLE: when sensing self goes wrong
Immunologic Research (2012)
